Compare AbCellera Biologics Inc (ABCL) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Under Armour Inc Class A — how do they compare? AbCellera Biologics Inc trades at $7.13 (market cap $2.35B), while Under Armour Inc Class A trades at $6.46 (market cap $2.87B). The key difference: Under Armour Inc Class A is the larger of the two by market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals.
| ABCL | UAA | |
|---|---|---|
Market Cap | $2.35B | $2.87B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $8.14 |
52-Week Low | $2.78 | $4.17 |
Enterprise Value | $1.99B | $4.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Under Armour (UAA) trades at $6.74, up 1.66% today, with a bullish technical signal from moving averages but bearish oscillators. Recent earnings show mixed results, with Q4 2026 beating expectations but Q1 2026 missing. The company faces declining revenue and negative net income margins, though international growth and a new Dodge collaboration offer potential catalysts. Cash flow remains negative, and the balance sheet shows rising debt-to-asset ratios, indicating financial strain.
The outlook is cautious due to weak North American sales and margin pressure, but analyst consensus leans hold with a $5.96 price target. Risks include consumer spending softness and execution challenges, while opportunities lie in international expansion and strategic partnerships. Investors should weigh deteriorating fundamentals against potential turnaround efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
